Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772992 | 0.99 | HRH3 (0.34) | HRH3CYP2C19HIF1AHTR2AHTR2C | |
| SCHEMBL5773572 | 0.81 | MAP4K4 (0.36) | — | |
| SCHEMBL21036376 | 0.75 | CHRM3 (0.33) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL21003237 | 0.74 | CHRM3 (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL21036396 | 0.73 | HTR2C (0.42) | HTR2AHTR2CHTR2BALOX15ALDH1A1 | |
| SCHEMBL21908515 | 0.71 | HTR2C (0.43) | HTR2AHTR2CHTR2BALOX15ALDH1A1 | |
| SCHEMBL17298716 | 0.70 | KDM4E (0.33) | HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL29428699 | 0.70 | KDM4E (0.33) | HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL19964203 | 0.70 | HTR2C (0.42) | HTR2AHTR2CHTR2BALOX15HTT | |
| SCHEMBL5777690 | 0.69 | HRH3 (0.47) | HRH3HIF1AALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | HRH3 170/4885CYP2C19 390/4885HIF1A 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.